Radiology:人工智能,为低剂量CT筛查肺结节“加装备”!

2021-11-03 shaosai MedSci原创

国家肺部筛查试验(NLST)和荷兰-比利时肺癌筛查试验显示,应用低剂量胸部CT对高危人群进行肺癌筛查可使肺癌死亡率降低20%-26%。

国家肺部筛查试验(NLST)和荷兰-比利时肺癌筛查试验显示,应用低剂量胸部CT对高危人群进行肺癌筛查可使肺癌死亡率降低20%-26%。肺癌在CT上通常表现为肺部结节。然而大多数结节是良性的,并不需要进一步的临床检查。现阶段,临床上已开发出了肺结节管理指南和数据驱动模型,用以减少假阳性的发现率,并进一步避免过度治疗,但要准确区分良性和恶性结节仍然是一个挑战。
近几年,使用卷积神经网络(CNN)的深度学习(DL)算法已成为分析医学图像的首选手段。一些研究通过使用公开的肺部图像数据库联盟的图像收集数据集,展示了CNN在预测肺部结节恶性风险方面的潜力。然而,这些研究使用了放射科医生提供的主观标签,并且缺乏一个客观且坚实的参考标准。
近日,发表在Radiology杂志的一项研究在CNN的基础上开发了一个用于对低剂量CT检测到的肺部结节进行恶性风险评估的DL算法,参考标准由组织病理学检查或至少2年的随访进行设定,并进行了外部验证,为临床肺癌的快速准确筛查及肺结节的良恶性判读提供了技术支持。
本项回顾性研究建立的DL算法是基于2002年至2004年间从国家肺部筛查试验中收集的16 077个结节(1249个恶性)中开发的。在2004年至2010年期间从丹麦肺癌筛查试验中收集的以下三个队列中进行了外部验证:一个包含所有883个结节(65个恶性)的完整队列和两个具有尺寸匹配(175个结节,59个恶性)和没有尺寸匹配(177个结节,59个恶性)的随机选择的良性结节的癌症富集队列。通过使用受试者工作特征曲线下的面积(AUC)来衡量算法的性能,并在全部队列中与Pan-Canadian 肺癌早期检测(PanCan)模型进行比较,在癌症富集队列中与由4名胸腔放射科医生、5名放射科住院医生和2名胸部专业医生组成的11名临床医生进行比较。
在全部队列中,DL算法的表现明显优于PanCan模型(AUC,0.93 [95% CI: 0.89, 0.96] vs 0.90 [95% CI: 0.86, 0.93];P = .046)。在癌症富集队列的随机良性结节(AUC,0.96 [95% CI: 0.93, 0.99] vs 0.90 [95% CI: 0.81, 0.98]; P = .11)和大小匹配的良性结节(AUC,0.86 [95% CI: 0.80, 0.91] vs 0.82 [95% CI: 0.74, 0.89]; P = .26)中,该算法的表现与胸部放射科医生相当。

图 丹麦肺癌筛查试验(DLCST)中的一个15毫米的部分实性恶性结节示例。该结节位于右上叶,条形图(右侧)显示,除了一位胸部放射科医生和一位肺科医生外,大多数临床医生都不认为该结节是恶性的。深度学习(DL)算法将这个结节正确地分类为恶性。
本研究成功地开发了一种深度学习算法,该算法可用于对低剂量CT检测到的肺部结节进行恶性肿瘤风险估计,且该算法在不同的筛查人群和方案中具有普遍性。该算法的判别性能可与临床专家相媲美。这种深度学习算法可以协助放射科医生对进行肺癌筛查的参与者进行准确的影像学判读,并可进一步减少不必要的手术。此外,该算法也有助于降低放射科医生的工作量,并减少肺癌筛查的成本。


原文出处:
Kiran Vaidhya Venkadesh,Arnaud A A Setio,Anton Schreuder.Deep Learning for Malignancy Risk Estimation of Pulmonary Nodules Detected at Low-Dose Screening CT.DOI:10.1148/radiol.2021204433

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1768908, encodeId=3b4d1e68908e8, content=<a href='/topic/show?id=351454e3d6' target=_blank style='color:#2F92EE;'>#CT筛查#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5473, encryptionId=351454e3d6, topicName=CT筛查)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=93a637925369, createdName=ms6747015003810650, createdTime=Wed Dec 15 21:04:50 CST 2021, time=2021-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423983, encodeId=9d8c1423983f4, content=<a href='/topic/show?id=3f482616064' target=_blank style='color:#2F92EE;'>#低剂量CT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26160, encryptionId=3f482616064, topicName=低剂量CT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8c83876884, createdName=xlxchina, createdTime=Fri Nov 05 02:04:50 CST 2021, time=2021-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480611, encodeId=5fb31480611e5, content=<a href='/topic/show?id=647d2615939' target=_blank style='color:#2F92EE;'>#低剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26159, encryptionId=647d2615939, topicName=低剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=97b17641126, createdName=ms1292405679162969, createdTime=Fri Nov 05 02:04:50 CST 2021, time=2021-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1066685, encodeId=d0001066685ed, content=好的, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=19b55641351, createdName=ms3000002003510203, createdTime=Wed Nov 03 20:30:04 CST 2021, time=2021-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1066684, encodeId=6cb710666842e, content=学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=232a3415946, createdName=12fc5fdem85暂无昵称, createdTime=Wed Nov 03 20:22:48 CST 2021, time=2021-11-03, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1768908, encodeId=3b4d1e68908e8, content=<a href='/topic/show?id=351454e3d6' target=_blank style='color:#2F92EE;'>#CT筛查#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5473, encryptionId=351454e3d6, topicName=CT筛查)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=93a637925369, createdName=ms6747015003810650, createdTime=Wed Dec 15 21:04:50 CST 2021, time=2021-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423983, encodeId=9d8c1423983f4, content=<a href='/topic/show?id=3f482616064' target=_blank style='color:#2F92EE;'>#低剂量CT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26160, encryptionId=3f482616064, topicName=低剂量CT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8c83876884, createdName=xlxchina, createdTime=Fri Nov 05 02:04:50 CST 2021, time=2021-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480611, encodeId=5fb31480611e5, content=<a href='/topic/show?id=647d2615939' target=_blank style='color:#2F92EE;'>#低剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26159, encryptionId=647d2615939, topicName=低剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=97b17641126, createdName=ms1292405679162969, createdTime=Fri Nov 05 02:04:50 CST 2021, time=2021-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1066685, encodeId=d0001066685ed, content=好的, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=19b55641351, createdName=ms3000002003510203, createdTime=Wed Nov 03 20:30:04 CST 2021, time=2021-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1066684, encodeId=6cb710666842e, content=学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=232a3415946, createdName=12fc5fdem85暂无昵称, createdTime=Wed Nov 03 20:22:48 CST 2021, time=2021-11-03, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1768908, encodeId=3b4d1e68908e8, content=<a href='/topic/show?id=351454e3d6' target=_blank style='color:#2F92EE;'>#CT筛查#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5473, encryptionId=351454e3d6, topicName=CT筛查)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=93a637925369, createdName=ms6747015003810650, createdTime=Wed Dec 15 21:04:50 CST 2021, time=2021-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423983, encodeId=9d8c1423983f4, content=<a href='/topic/show?id=3f482616064' target=_blank style='color:#2F92EE;'>#低剂量CT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26160, encryptionId=3f482616064, topicName=低剂量CT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8c83876884, createdName=xlxchina, createdTime=Fri Nov 05 02:04:50 CST 2021, time=2021-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480611, encodeId=5fb31480611e5, content=<a href='/topic/show?id=647d2615939' target=_blank style='color:#2F92EE;'>#低剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26159, encryptionId=647d2615939, topicName=低剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=97b17641126, createdName=ms1292405679162969, createdTime=Fri Nov 05 02:04:50 CST 2021, time=2021-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1066685, encodeId=d0001066685ed, content=好的, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=19b55641351, createdName=ms3000002003510203, createdTime=Wed Nov 03 20:30:04 CST 2021, time=2021-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1066684, encodeId=6cb710666842e, content=学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=232a3415946, createdName=12fc5fdem85暂无昵称, createdTime=Wed Nov 03 20:22:48 CST 2021, time=2021-11-03, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1768908, encodeId=3b4d1e68908e8, content=<a href='/topic/show?id=351454e3d6' target=_blank style='color:#2F92EE;'>#CT筛查#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5473, encryptionId=351454e3d6, topicName=CT筛查)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=93a637925369, createdName=ms6747015003810650, createdTime=Wed Dec 15 21:04:50 CST 2021, time=2021-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423983, encodeId=9d8c1423983f4, content=<a href='/topic/show?id=3f482616064' target=_blank style='color:#2F92EE;'>#低剂量CT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26160, encryptionId=3f482616064, topicName=低剂量CT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8c83876884, createdName=xlxchina, createdTime=Fri Nov 05 02:04:50 CST 2021, time=2021-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480611, encodeId=5fb31480611e5, content=<a href='/topic/show?id=647d2615939' target=_blank style='color:#2F92EE;'>#低剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26159, encryptionId=647d2615939, topicName=低剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=97b17641126, createdName=ms1292405679162969, createdTime=Fri Nov 05 02:04:50 CST 2021, time=2021-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1066685, encodeId=d0001066685ed, content=好的, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=19b55641351, createdName=ms3000002003510203, createdTime=Wed Nov 03 20:30:04 CST 2021, time=2021-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1066684, encodeId=6cb710666842e, content=学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=232a3415946, createdName=12fc5fdem85暂无昵称, createdTime=Wed Nov 03 20:22:48 CST 2021, time=2021-11-03, status=1, ipAttribution=)]
    2021-11-03 ms3000002003510203

    好的

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1768908, encodeId=3b4d1e68908e8, content=<a href='/topic/show?id=351454e3d6' target=_blank style='color:#2F92EE;'>#CT筛查#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5473, encryptionId=351454e3d6, topicName=CT筛查)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=93a637925369, createdName=ms6747015003810650, createdTime=Wed Dec 15 21:04:50 CST 2021, time=2021-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423983, encodeId=9d8c1423983f4, content=<a href='/topic/show?id=3f482616064' target=_blank style='color:#2F92EE;'>#低剂量CT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26160, encryptionId=3f482616064, topicName=低剂量CT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8c83876884, createdName=xlxchina, createdTime=Fri Nov 05 02:04:50 CST 2021, time=2021-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480611, encodeId=5fb31480611e5, content=<a href='/topic/show?id=647d2615939' target=_blank style='color:#2F92EE;'>#低剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26159, encryptionId=647d2615939, topicName=低剂量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=97b17641126, createdName=ms1292405679162969, createdTime=Fri Nov 05 02:04:50 CST 2021, time=2021-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1066685, encodeId=d0001066685ed, content=好的, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=19b55641351, createdName=ms3000002003510203, createdTime=Wed Nov 03 20:30:04 CST 2021, time=2021-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1066684, encodeId=6cb710666842e, content=学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=232a3415946, createdName=12fc5fdem85暂无昵称, createdTime=Wed Nov 03 20:22:48 CST 2021, time=2021-11-03, status=1, ipAttribution=)]
    2021-11-03 12fc5fdem85暂无昵称

    学习一下

    0

相关资讯

Radiology:你还在为胸部X线片上的胸部X线片烦恼吗?

胸部X线片是最常用的影像学检查之一。多项研究表明,当对基线胸部X线片进行重新检查时,高达90%的“遗漏”肺癌结节可以被发现,且显示肿块的大小已经增大。

Radiology:卷积神经网络,使评估肺结节每天的体积变化成为可能!

美国国家肺部筛查试验显示,低剂量CT筛查肺癌是一种可降低总死亡率的具有经济效益的检查手段。

肺内小结节,估计80%的年轻同行都没考虑这个诊断

病史女性,61岁,肺小结节会诊影像图片不是肺癌、不是肺癌、不是肺癌,重要事情说三遍!你的诊断是什么?

肺结节抗炎后不吸收就建议切除?

46男性,不吸烟。因感冒发热,做CT检查发现肺实性结节1.6cm。用了头孢加左氧消炎7天后,复查CT检查没有变化,当地继续予莫西沙星抗炎治疗中。

肺结节是良性还是恶性?体检发现肺结节怎么办?一招教你分辨

​随着人们对健康的重视和检查技术的进步,近几年,肺结节的检出率很高,很多人在发现肺结节后会很担心,反复检查或者去问医生,想知道肺结节是良性还是恶性。肺结节究竟是什么?是恶性肿瘤吗?今天来一起一探究竟。